JMP Securities upgraded shares of Proteon Therapeutics (NASDAQ:PRTO) from a market perform rating to an outperform rating in a report issued on Monday morning, MarketBeat Ratings reports.
PRTO has been the topic of a number of other research reports. Zacks Investment Research cut Proteon Therapeutics from a hold rating to a sell rating in a research report on Friday, January 18th. HC Wainwright set a $3.00 price target on Proteon Therapeutics and gave the company a buy rating in a research report on Friday, January 25th. Finally, Maxim Group started coverage on Proteon Therapeutics in a research report on Tuesday, October 30th. They set a buy rating and a $5.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Proteon Therapeutics currently has an average rating of Buy and a consensus target price of $3.50.
Shares of NASDAQ PRTO opened at $2.99 on Monday. Proteon Therapeutics has a one year low of $1.50 and a one year high of $3.10. The firm has a market cap of $56.13 million, a PE ratio of -1.40 and a beta of 0.77.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.
Recommended Story: Why Net Income is Important to Investors
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.